# CELL GROWTH INHIBITION AND ESTROGEN ACTION

> **NIH NIH R01** · BAYLOR COLLEGE OF MEDICINE · 1991 · $268,804

## Abstract

DESCRIPTION (Adapted from the applicant's abstract):  The long term
objective of the proposed research is to precisely define the function of
type II binding sites in normal and malignant cells.  Nuclear type II sites
bind methyl p-hydroxyphenyllactate (MeHPLA) and this compound appears to
regulate normal and malignant cell growth through this binding interaction.
Although type II binding sites may be closely coupled to DNA replication
and cellular proliferation, the precise function of this nuclear protein
and MeHPLA in normal and malignant cell regulation is unknown.  The general
goal of this proposal is to study type II gene structure and expression and
subsequent effects on cellular proliferation.  In order to accomplish this
goal, the following aims are proposed:  determine the biological origin of
MeHPLA in mammalian cells, synthesize an affinity ligand, and purify
nuclear type II sites from the rat or rabbit uterus.  Type II sites will be
extracted from rat or rabbit uterine nuclei and purified by chromatographic
techniques for separation based on molecular size, charge and ligand
binding specificity (affinity chromatography).  Monoclonal and polyclonal
antibodies will be generated against purified type II antigen and these
immunological probes will be employed for qualitative and quantitative
analysis of type II sites and the estrogen receptor.  Type II antibodies
and oligonucleotide probes will be used to screen cDNA libraries for the
type II gene(s).  The gene will be characterized and the cDNA utilized as a
probe to study estrogen, MeHPLA, tamoxifen and carcinogen
(dimethylbenz[a]anthracene) modulation of type II gene expression in normal
(rat uterus) and malignant cells in vitro (human breast cancer cells) and
in vivo (rat and mouse mammary tumor).

## Key facts

- **NIH application ID:** 3173044
- **Project number:** 2R01CA035480-07
- **Recipient organization:** BAYLOR COLLEGE OF MEDICINE
- **SAM.gov UEI:** FXKMA43NTV21
- **Principal Investigator:** BARRY Matthew MARKAVERICH
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1991
- **Award amount:** $268,804
- **Award type:** 2
- **Project period:** 1983-08-01 → 1994-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3173044

## Citation

> US National Institutes of Health, RePORTER application 3173044, CELL GROWTH INHIBITION AND ESTROGEN ACTION (2R01CA035480-07). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3173044. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*